Table S1. Demographic and clinical data of 28 women with a history of cTMA and pregnancy.

Characteristic	All	Before cTMA	With cTMA	After cTMA
			Pregnancy condition	
Women	28	16	13	10
Pregnancies	74[a]	39	13[a]	22[b]
Pregnancies before 2012[c]	40 (54)	30 (77)	5 (38)	5 (23)
Age at delivery	29 (24, 34)	27 (20, 32)	30 (26, 34)	30 (28, 34)
Age at diagnosis of cTMA	30 (23, 40)	38 (29, 52)	28 (24, 34)	20 (13, 24)
Biopsy confirming TMA	19 (68)	11 (69)	8 (62)	6 (60)
Eculizumab use				
Continuous before-during-after pregnancy	2 (7) W/3 (4) P	-	-	2 (20) W/3 (14) P
At pregnancy for postpartum P-cTMA	4 (14) W/4 (5) P	-	4 (31) W/4 (31) P	-
Not related to pregnancy	8 (29) W	8 (50) W	-	-
Plasma exchanges or infusions				
Continuous before-during-after pregnancy	4 (7) W/7 (10) P	-	1 (8) W/1 (8) P (switch to ecu)	4 (40) W/6 (27) P
At pregnancy for postpartum P-cTMA	7 (25) W/7 (10) P	-	7 (54) W/7 (54) P (2 x switch to ecu)	-
Not related to pregnancy	7 (25) W (6 x switch to ecu)	7 (44) W (6 x switch to ecu)	-	-
Impaired kidney function before pregnancy	8 (29) W/16 (22) P	-	2 (15) KTR/2 (15) P	7 (70) W/14 (64) P
Dialysis at last follow-up	4 (14)	1 (6)	3 (23)	1 (10)
Kidney transplant at last follow-up	8 (29)	6 (38)	2 (15)	3 (30)
Deaths	4 (14),2 HD, 2 KTR	2 (13) KTR	2 (15) HD	1 (10) HD
Age at death, years	49 (41-55)	44-55	41-54	54

Data are given as n (%) or median (p25, p75)

[a], includes one set of twins; [b], 3 women received aspirin during 3 pregnancies; [c], before use of eculizumab in our center

cTMA, complement mediated thrombotic microangiopathy; KTR, kidney transplant recipient; HD, hemodialysis

W, women; P, pregnancies; ecu, eculizumab

Haninger-Vacariu et al, Kidney Med, *"Pregnancy in Complement Mediated Thrombotic Microangiopathy: Maternal and Neonatal Outcomes"*

Table S2. Genetic variants, risk haplotypes, and copy number variations of 28 women with cTMA and a history of pregnancy.

Patient ID	Gene	Variant[a]	MAF %[b] (gnomAD global)	MAF %[c] (1000G global)	Risk haplotype	(Variants) Copy number of *CFHR-1,2,3,5*
1	-	-	-	-	*CFH* H3, het; *CD46*ggaac, het	WT
2	*THBD*	p.E560Q het (LPV)	0.0018%	0.02%	*CFH* H3, het	WT
3	*CFHR5*	p.G228A het (VUS)	0.0016%	0	*CFH* H3, hom	WT
4	-	-	-	-	*CFH* H3, het; *CD46*ggaac, hom	WT
5	-	-	-	-	*CD46*ggaac, hom	WT
6	*C3*	p.D61N het (VUS)	0.002%	0	*CFH* H3, het; *CD46*ggaac, hom	WT
7	*CFH*	p.C1032* het (PV)	0	0	*CD46*ggaac, hom; *CFH* H8, het	het del*CFHR1,3*
8	-	-	-	-	*CFH* H3, hom; *CD46*ggaac, het	WT
9	-	-	-	-	*CFH* H3, het	WT
10	*CD46*	p.E142Q het (VUS)	0.008%	0	*CFH* H3, het	het del*CFHR1,3*
11	-	-	-	-	-	het del*CFHR1,3*
12	*CFHR5*	c.479_480insA het (VUS)	0.2%	0.08%	*CD46*ggaac, het	WT
13	*CFH*	p.N516K het (VUS)	0.03%	0.02%	*CFH* H3 het; *CFH* H8, het *CD46*ggaac, hom	WT
14	-	-	-	-	*CFH* H3, het; *CD46*ggaac, hom	WT
15	-	-	-	-	*CFH* H3, het; *CD46*ggaac, hom	WT
16	*C3*	p.K104E het (VUS)	0	0	*CFH* H3, het; *CD46*ggaac, het	WT
	C3	p.D1457H het (VUS)	0.03%	0.16%		
17	*CFI*	p.I416L het (VUS)	0.03%	0.09%	*CD46*ggaac, het	het del*CFHR1,3*
18	*C3*	p.V1296A het (VUS)	0	0	*CFH* H3, het; *CD46*ggaac, het	het del*CFHR1,3*
19	-	-	-	-	*CFH* H3, het; *CD46*ggaac, hom	n.a.
20	-	-	-	-	*CFH* H3, het	WT
21	-	-	-	-	*CFH* H3, hom; *CD46*ggaac, het	WT
22	*CFI*	p.G342E het (LPV)	0.0012%	0	*CFH* H3, het; *CD46*ggaac, het	WT
	CD46	p.D257Vfs41 het (LPV)	0	0		
23	*CD46*	p.E234K het (VUS)	0.0056%	0.02%	*CFH* H3, het; *CD46*ggaac, het	n.a.
24	*CFH*	p.D748Nfsa10 het (PV)	0	0	*CFH* H3, het; *CD46*ggaac, het	WT
25	-	-	-	-	*CD46*ggaac het	het del*CFHR1,3*
26	-	-	-	-	-	het del*CFHR1,3*
27	-	-	-	-	*CD46*ggaac, het	n.a.
28	*CFH*	p.S1191L het (PV)	0	0	*CD46*ggaac, het	elevated signal of *CFHR1* exon 6 due to mutations in *CFH* (resulting from gene conversion between *CFH* and *CFHR1)*
	CFH	p.V1197A het (PV)	0.0004%	0		

[a], Variant classification according to the American College of Genetics and Genomics in parenthesis
[b], Minor allele frequency (MAF) of the variant allele in the overall (global) gnomAD population (https://gnomad.broadinstitute.org/)
[c], Minor allele frequency (MAF) of the variant allele in the overall (global) 1000Genomes population (https://www.internationalgenome.org/)

cTMA, complement mediated thrombotic microangiopathy; het, heterozygous; hom, homozygous; PV, pathogenic variant; LPV, likely pathogenic variant; VUS, variant of unknown significance; WT, wild-type; n.a., not analyzed

Table S2, discussion.

Papers reporting on the genetic background of pregnancy-associated aHUS usually list all the identified rare complement gene variants, including those classified as VUS. In our cohort, there were 5 cases, or 17% of total patients, with variations classified as PV or LPV (patient 2, 7, 22, 24 and 28). There were a further 7 patients with variations classified as VUS in the *CFH*, *CFI*, *CD46* or *C3* genes. Altogether, this is 42% of all patients with a rare complement gene variation, which is comparable to previous reports.

A multicenter study (France, United Kingdom, Italy, PMID: 28596415) aimed to identify presentation, outcomes, and frequency of complement alternative pathway gene variants with an international cohort of 87 patients with p-HUS. Novel or rare variants of complement genes were present in 56% (49/87) of women and this list included VUS variations as well (for example the *CFH* p.N516K identified in our cohort as well, or the *CFI* p.I416L which they assessed as pathogenic).
In a retrospective study of the Spanish P-aHUS Registry (PMID: 28911789), 9 out of 22 patients (41%) were reported to carry a complement abnormality in the aHUS-associated candidate genes, although not all of the listed variants are pathogenic based on the current ACMG guidelines *(*e.g. *C3* p.S1619R is likely benign according to the complement database, www.complement-db.org).
A further study by Rondeau et al. (PMID: 34515154) recorded that pathogenic variants were identified in 20 out of 33 (60.6%) tested aHUS patients who became pregnant. Among them, patients carrying only risk haplotypes/polymorphisms were also listed; there were only 7 patients with (L)PV variations, according to the classification of complement-database.org.
In a recent study by Fakhouri et al. (PMID: 33826112), the proportion of women with pregnancy-associated aHUS carrying pathogenic variant(s) in complement genes and/or anti-CFH antibody was found to be 45.1% (23/51). The detailed list of the identified pathogenic variations was not available for review.

Of note, conflicting interpretations of pathogenicity are available for some of the variations listed as VUS in our paper.

The *CFI* p.I416L variation - classified as pathogenic in PMID: 28596415 - was reported to dramatically decrease the FI level in cell culture supernatants as detected by enzyme-linked immunosorbent assay (ELISA) and western blotting, as well as to reduce the amount of intracellular FI. (PMID: 20016463). It was identified in several aHUS patients, however, based on the study by Osborne et al (PMID: 29500241), the allele frequency in aHUS patients was not found to be higher than the MAF in healthy populations, thus the complement database classified it as of uncertain significance.
The *CD46* p.E234K was reported as an aHUS associated mutation in PMID: 26054645. However, as no other appearance of the corresponding variation was described in the literature and its frequency is 0.0056% in gnomAD and 0.02% in 1000Genomes, we classified it as VUS.
In addition, mutations that are absent from (*C3* p.V1296A, *C3* p.K104E) or have very low frequency in large population studies (*C3* p.D61N, gnomAD: 0.002%, 1000Genome: 0), were classified as of uncertain significance, because we did not find records of them in other complement mediated TMA patients and no data is available on their functional role.

References:
PMID: 28596415, Bruel A, Kavanagh D, Noris M, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol 2017; 12: 1237–1247.
PMID: 28911789, Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int 2018; 93: 450–459.
PMID: 34515154, Eric Rondeau et al, Pregnancy in Women with Atypical Hemolytic Uremic Syndrome. Nephron. 2022;146(1):1-10.
PMID: 33826112, Fakhouri et al. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. J Nephrol. 2021 Oct;34(5):1581-1590.
PMID: 20016463, Bienaime et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 2010 Feb;77(4):339-349.
PMID: 29500241,Osborne et al. Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. J Immunol. 2018 Apr;200(7):2464-2478.

Table S3. Maternal risk factors for worse delivery outcomes of 47 live births.

Characteristic	All	Pregnancy condition		
		Before cTMA	With cTMA	After cTMA
Women with live births, n	26	14	8	9
Live births, n	47[a]	22	9[a]	16
In vitro fertilization	3 (6)	0	3 (33)	0
Current smoking	15 (32)	11 (50)	2 (22)	2 (13)
Hypertension [b]	20 (43)	2 (9)	5 (56)	13 (81)
Proteinuria [b]	19 (40)	2 (9)	4 (44)	13 (81)
Impaired kidney function [c]	14 (30)	0	2 (22)	12 (75)
Pregnancies in KTRs	8 (17)[d]	0	2 (22)[e]	6 (38)[f]

Data are given as n (%)

[a], includes one set of twins; [b], during pregnancy; [c], elevated serum creatinine or proteinuria before pregnancy; [d], five women; [e], two women; [f], three women

cTMA, complement mediated thrombotic microangiopathy; KTR, kidney transplant recipient

Table S4. Individual delivery and neonatal outcomes of 74 pregnancies in 28 women with cTMA.

Mother and pregnancy ID	Pregnancy before, with, after cTMA	Pregnancy outcome	Gestational age (week+days)	Time of delivery	Mode of delivery	Infants sex	Birth weight (g)	Birth weight assessment	Birth weight centile	Birth weight z-score	Birth length (cm)	Birth length centile	Birth length z-score	Birth head circumference (cm)	Birth head circumference centile	Birth head circumference z-score	Apgar score (1 minute)	Apgar score (5 minutes)	Apgar score (10 minutes)	Admission to NICU	Malformations*	Weight at follow-up (g)	Weight at follow-up centile	Weight at follow-up z-score	Length at follow-up (cm)	Length at follow-up centile	Length at follow-up z-score	Head circumference at follow-up (cm)	Head circumference at follow-up centile	Head circumference at follow-up z-score	Breastfeeding	Age at follow-up (days)	Infants age as of December 2020 (years)
1-1	Before	L	35+6	Late PT	C section	m	2117	Low BW	9,00	-1,35	49	79,00	0,81	33,0	62,00	0,30	7	9	9	-	-	2880	16	-1,00	50,0	52	0,06	35,0	66	0,42	-	25,0	8,3
1-2	With	S	33+1	Moderate PT	Vaginal	f	1860	Low BW			41			29,0																			
1-3	After	L	35+0	Late PT	Vaginal	f	2350	Low BW	49,00	-0,03	48	85,00	1,04	33,0	85,00	1,03	8	10	10			3300	42	-0,21	51,0	57	0,18	34,0	26	-0,64	-	43,0	1,5
1-4	After	A (i)	<12																														
2-1	With	M	18																														
2-2	After	M	7																														
2-3	After	M	9+6																														
3-1	Before	M	<12																														
3-2	Before	L	40	Full term	Vaginal	m	2650	Normal BW	1	-2,21	46	0,99	-3,04	32,5	1	-2,38	9	10	na	-	-	5100	15	-1,04	54,0	0,99	-2,61	38,0	10	-1,3	na	67,0	21,0
3-3	Before	L	40	Full term	Vaginal	f	3100	Normal BW	19	-0,88	49	7	-1,45	34,0	25	-0,69	9	10	na	-	-	4330	59	0,22	52,5	26	-0,63	38,5	95	1,64	na	36,0	18,5
3-4	Before	M	<12																														
4-1	With	L	27+2	Extremely PT	C section	f	888	Extremely low BW	42,00	-0,20	35	47,00	-0,35	24,0	39,00	-0,29	5	7	9	Yes	-	900	0,99	-7,14	34,5	0,99	-7,86	24,5	0,99	-7,92	-	25,0	19,0
5-1	Before	L	41+0	Full term	C section	m	3270	Normal BW	15	-1,04	52	32	-0,48	36,0	53	0,08	na	na	na	-	-	na	na	na	na	na	na	na	na	na	Yes	na	39,1
5-2	Before	L	40+5	Full term	C section	f	3500	Normal BW	46	-0,11	50	17	-0,94	34,0	19	-0,86	9	10	10	-	Yes	4400	39	-0,29	57,0	84	0,98	37,5	58	0,2	-	36,0	31,2
6-1	Before	A (i)	na																														
6-2	Before	L	38+3	Full term	C section	m	3365	Normal BW	48	-0,05	52	59	0,24	36,5	85	1,05	9	10	10	-	Yes	5150	85	1,05	55,0	54	0,11	39,0	93	1,45	Yes	40,0	15,0
7-1	After	M	12																														
7-2	After	L	37+0	Full term	Vaginal	m	3082	Normal BW	48	-0,04	50	47	-0,08	34,0	39	-0,27	8	10	10	-	-	4460	68	0,47	56,0	87	1,14	36,0	26	-0,65	Yes	46,0	1,9
8-1	With	S	31+1	Very PT	C section	m	1210	Very low BW			na			34,0																			
9-1	na	na	na	na	C section	f	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	29,3
10-1	Before	M	6																														
10-2	Before	M	7																														
10-3	With	L	32+0	Moderate PT	C section	f	1220	Very low BW	11,00	-1,25	38	11,00	-1,23	29,0	54,00	0,11	8	9	9	Yes	-	2300	1	-2,25	42,5	0,99	-3,57	32,5	12	-1,16	-	49,0	2,3
11-1	Before	L	38+0	Full term	C section	f	2890	Normal BW	25	-0,67	47	7	-1,48	33,0	16	-1,00	9	10	10	-	-	3750	39	-0,29	52,0	36	-0,37	36,5	67	0,44	-	38,0	16,9
12-1	With	M	18+3																														
12-2	After	L	34+5	Late PT	Vaginal	f	1940	Low BW	11,00	-0,87	44	36,00	-0,35	31,0	44,00	-0,16	9	9	10	-	-	2482	4	-1,77	48,0	27	-0,62	33,0	23	-0,74	-	28,0	3,4
13-1	Before	L	39+0	Full term	C section	m	3760	Normal BW	74	0,64	53	68	0,48	33,0	4	-1,77	9	10	10	-	Yes	4410	75	0,69	56,0	92,0	1,4	37,5	82	0,92	Yes	26,0	18,2
13-2	Before	L	38+3	Full term	C section	f	3030	Normal BW	21	-0,82	51	42	-0,19	33,0	6	-1,53	9	10	10	-	Yes	4860	63	0,32	56,0	63	0,34	na	na	na	-	45,0	7,2
13-3	With	L	38+0	Full term	C section	f	3240	Normal BW	56	0,15	49	27	-0,61	34,0	41	-0,23	9	10	10	-	-	4540	81	0,89	55,0	83	0,97	36,5	59	0,24	-	40,0	5,1
14-1	Before	M	<12																														
14-2	Before	L	40+0	Full term	Vaginal	m	3950	Normal BW	77	0,74	53	50	0,00	na	na	na	na	na	na	-	-	na	na	na	na	na	na	na	na	na	Yes	na	43,9
14-3	Before	L	43+1	Full term	Vaginal	f	3550	Normal BW	44	-0,15	49	7	-1,47	34,0	15	-1,05	10	10	na	-	-	3900	9	-1,33	53,0	12	-1,19	na	na	na	na	29,0	42,2
14-4	Before	M	<12																														
14-5	Before	L	41+0	Full term	Vaginal	f	3900	Normal BW	77	0,75	50	16	-1,00	35,0	44	-0,15	9	10	10	-	-	4900	72	0,57	na	na	na	na	na	na	Yes	34,0	36,5
14-6	Before	L	38+6	Full term	Vaginal	f	3565	Normal BW	59	0,24	51	37	-0,34	34,0	17	-0,95	9	10	10	-	-	4260	49	-0,03	54,0	48	-0,05	38,0	82	0,92	Yes	33,0	27,2
15-1	Before	M	<12																														
15-2a	With	L	31+5	Very PT	C section	f	1340	Very low BW	22,00	-0,78	38	14,00	-1,08	28,0	35,00	-0,38	7	9	9	Yes	Yes	2790	16	-1,01	49,5	58	0,19	33,9	51	0,02	-	42,0	2,5
15-2b	With	L	31+5	Very PT	C section	f	1495	Very low BW	36,00	-0,35	40	31,00	-0,51	29,5	74,00	0,64	8	9	9	Yes	-	2920	24	-0,7	52,0	94	1,53	34,4	67	0,44	-	42,0	2,5
16-1	With	L	40+6	Full term	C section	f	4450	Normal BW	98	2,07	53	66	0,40	38,0	99	2,19	8	10	10	Yes	-	6150	85	1,04	63,0	99	2,42	42,0	100	2,7	-	63,0	9,1
16-2	After	L	37+3	Full term	C section	f	3130	Normal BW	56	0,16	49	35	-0,38	35,0	75	0,68	7	7	9	-	-	5350	93	1,50	60,0	100	2,87	39,5	99	2,2	Yes	53,0	6,6
16-3	After	L	38+0	Full term	C section	m	3150	Normal BW	48	-0,06	51	60	0,26	33,5	27	-0,62	6	8	9	-	-	na	na	na	na	na	na	na	na	na	na	na	5,5
16-4	After	L	37+5	Full term	C section	f	3070	Normal BW	45	-0,12	53	89	1,22	34,0	44	-0,14	8	10	10	-	-	4610	63	0,33	56	78	0,78	39	96	1,72	na	52,0	0,1
17-1	After	L	37+3	Full term	Vaginal	m	3110	Normal BW	42	-0,19	51	57	0,17	33,0	13	-1,11	9	10	10	-	-	4100	66	0,40	54,5	81	0,89	37,5	88	1,16	-	36,0	10,9
17-2	After	L	40+3	Full term	Vaginal	m	3956	Normal BW	74	0,64	52	37	-0,33	36,0	58	0,21	9	10	10	-	-	5900	93	1,48	55,0	29	-0,56	39,0	81	0,87	-	37,0	9,1
17-3	After	S	33+3	Moderate PT	Vaginal	m	2230	Low BW			46			na																			
17-4	After	L	36+0	Late PT	Vaginal	m	3410	Normal BW	94,00	1,54	49	77,00	0,74	36,0	99,00	2,25	7	8	9	-	-	5180	99	2,38	55,0	92	1,39	40,0	100	3,54	-	41,0	4,6
17-5	After	L	38+2	Full term	Vaginal	m	3950	Normal BW	91	1,36	52	61	0,29	35,0	50	-0,01	9	10	10	Yes	-	4970	92	1,43	57,5	98	2,06	38,5	95	1,63	-	33,0	1,4
18-1	With	L	39+1	Full term	Vaginal	m	2685	Normal BW	3	-1,89	50	19	-0,86	33,0	4	-1,80	na	na	10	Yes	-	3930	35	-0,38	53,0	37	-0,34	38,0	87	1,13	-	31,0	2,9
19-1	With	L	41+0	Full term	Vaginal	m	3200	Normal BW	12	-1,19	na	na	na	na	na	na	na	na	na	-	-	na	na	na	na	na	na	na	na	na	Yes	na	31,0
19-2	With	L	40+0	Full term	Vaginal	m	3200	Normal BW	17	-0,96	na	na	na	na	na	na	na	na	na	-	-	na	na	na	na	na	na	na	na	na	Yes	na	29,5
20-1	After	M	<12																														
20-2	After	L	38+2	Full term	Vaginal	m	3170	Normal BW	33	-0,44	52	61	0,29	34,0	23	-0,74	9	10	10	-	-	4490	32	-0,46	57,0	75	0,66	38,0	57	0,18	Yes	49,0	0,3
21-1	Before	L	41+3	Full term	C section	f	4090	Normal BW	87	1,12	52	44	-0,15	35,0	41	-0,22	9	10	10	-	-	4900	63	0,32	57,0	77	0,75	37,0	34	-0,41	-	35,0	17,2
21-2	Before	L	40+2	Full term	C section	m	3560	Normal BW	41	-0,22	50	12	-1,16	36,0	59	0,24	9	10	10	-	-	3950	14	-1,08	55,0	49	-0,03	37,0	35	-0,38	Yes	31,0	15,3
22-1	After	L	39+1	Full term	Vaginal	f	3010	Normal BW	20	-0,84	53	79	0,82	33,0	10	-1,26	9	10	10	-	-	4000	46	-0,10	56,0	92	1,42	36,0	40	-0,25	-	33,0	11,3
22-2	After	L	38+2	Full term	Vaginal	m	3340	Normal BW	48	-0,05	50	28	-0,58	33,0	7	-1,47	9	10	10	-	Yes	4830	64	0,35	55,0	46	-0,1	38,5	80	0,83	Yes	45,0	8,2
22-3	After	L	40+3	Full term	Vaginal	m	3720	Normal BW	54	0,11	52	37	-0,33	35,0	29	-0,56	9	10	10	-	-	4850	33	-0,45	57,5	61	0,28	39,5	82	0,93	Yes	44,0	2,3
23-1	Before	L	na	na	Vaginal	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	19,6
23-2	Before	L	na	na	C section	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na	15,0
24-1	Before	L	40+3	Full term	Vaginal	m	na	na	na	na	na	na	na	na	na	na	na	na	na	-	-	na	na	na	na	na	na	na	na	na	na	na	11,8
24-2	With	L	35	Late PT	Vaginal	m	na	na	na	na	na	na	na	na	na	na	na	na	na	-	-	na	na	na	na	na	na	na	na	na	na	na	18,7
25-1	After	L	39+2	Full term	Vaginal	m	3130	Normal BW	18	-0,91	51	32	-0,47	35,0	38	-0,30	9	10	10	-	Yes	4910	96	1,81	58	100	2,8	38	95	1,67	Yes	20,0	0,4
26-1	Before	L	41+2	Full term	Vaginal	m	3420	Normal BW	23	-0,74	51	17	-0,94	35,0	24	-0,72	9	10	10	-	-	4215	19	-0,87	55,5	48	-0,04	39,5	94	1,52	-	29,0	0,9
27-1	Before	M	na																														
27-2	Before	M	na																														
27-3	Before	A (i)	6																														
27-4	Before	L	38+2	Full term	C section	m	3485	Normal BW	61	0,29	49	16	-1,01	34,5	35	-0,38	9	10	10	-	-	4820	95	1,67	54,3	81	0,87	36,0	48	-0,04	Yes	27,0	6,9
27-5	Before	M	na																														
27-6	Before	M	na																														
27-7	Before	M	na																														
27-8	Before	A (i)	9+1																														
27-9	With	A (i)	20																														
28-1	Before	L	40+0	Full term	Vaginal	m	4100	Normal BW	86	1,08	55	86	1,09	na	na	na	9	10	10	-	-	na	na	na	na	na	na	na	na	na	Yes	na	47,7
28-2	Before	A (i)	6																														
28-3	Before	A (i)	6																														
Life birth missing data	0	0	3	3	0	5	5	5	5	7	7	7	9	9	9	10	10	12	2	5	11	11	11	12	12	12	14	14	14	7	10	0	

Miscarriages, abortions and stillbirths marked grey

cTMA, complement mediated thrombotic microangiopathy
M, miscarriage; A(i), induced abortion; L, live birth; S, stillbirth
PT, preterm; na, not available
m, male; f, female
BW, birth weight
NICU, neonatal intensive care unit

Malformations include: hemangioma, hip dysplasia (2 infants), patent foramen ovale & atrioseptal defect 2, pigmeted mole, pigeon toes, pigeon toes & frenulum of tongue

Table S5. Characteristics of 46 live births according to infant sex[a].

Characteristic	Female infants	Male infants
Women, n	14	19
Infants, n	19[b]	27
Gestational age (weeks)	38 (35, 41)	39 (38, 40)
Term vs. preterm		
Full term	12 (63)	23 (85)
Late preterm	2 (11)	3 (11)
Moderate preterm	1 (5)	0
Very preterm	2 (11)	0
Extremely preterm	1 (5)	0
Mode of delivery,		
Caesarean section	12 (63)[b]	8 (30)
Vaginal delivery	7 (37)	19 (70)
Induction of labor	2 (29)	7 (37)
Weight at birth		
Grams	3085 (2043, 3435)	3353 (3120, 3643)
Centile	45 (22, 56)	45 (18, 68)
Birth weight categories		
Normal birth weight	12 (63)	23 (85)
Low birth weight	2 (11)	1 (4)
Very low birth weight	3 (16)	0
Extremely low birth weight	1 (5)	0
Size for gestational age		
Small	0	3 (11)
Appropriate	17 (90)	19 (70)
Large	1 (5)	2 (7)
Length at birth		
Centimeter	49 (44, 51)	51 (50, 52)
Centile	33 (14, 60)	40 (28, 61)
Head circumference at birth		
Centimeter	34 (31, 34)	34 (33, 36)
Centile	41 (25, 54)	32 (10, 56)
Apgar score		

1 minute	9 (8, 9)	9 (9, 9)
5 minutes	10 (9, 10)	10 (10, 10)
10 minutes	10 (9, 10)	10 (10, 10)
Admission to NICU	5 (26)	2 (7)
Malformations	2 (11)	5 (19)
Number of neonates per pregnancy condition		
Before cTMA	7 (37)	14 (52)
With cTMA	6 (32)	3 (11)
After cTMA	6 (32)	10 (37)
Breastfeeding	5 (26)	15 (56)

Data are given as n (%) or median (p25, p75)

[a], excluding one with unknown sex and mother lost to follow-up

[b], including one set of twins

n, number; NICU, neonatal intensive care unit; cTMA; complement mediated thrombotic microangiopathy

Table S6. Neonatal outcomes of 46 infants born **a)** before manifestation of cTMA (n=22), **b)** related to a cTMA onset or recurrence (n=9, including one set of female twins), **c)** after manifestation of cTMA (n=16) according to neonatal sex [a].

a)

Characteristic	Female infants (n=7)		Male infants (n=14)	
	Birth	Follow-up	Birth	Follow-up
Age at follow-up (days)	-	36 (29-38)	-	31 (25-67)
Weight (g)	3525 (2890-4090)	4365 (3750-4900)	3425 (2117-4100)	4410 (2880-5150)
Weight (centile)	45 (19-87)	49 (9-72)	45 (1-86)	49 (14-95)
Weight gain velocity (g/week)	-	169 (85-239)	-	214 (88-346)
Length (cm)	50 (47-52)	53 (52-57)	52 (46-55)	54 (50-56)
Length (centile)	12 (7-44)	36 (12-84)	44 (11-86)	53 (<1-92)
Length gain velocity (cm/week)	-	1.0 (0.8-1.4)	-	0.8 (0.3-1.4)
Head circumference (cm)	34 (33-35)	37 (37-39)	34 (33-37)	38 (35-39)
Head circumference (centile)	22 (15-44)	63 (34-95)	44 (1-85)	66 (10-93)
Head growth (cm/week)	-	0.7 (0.4-0.9)	-	0.6 (0.2-1.2)
NICU	0	-	0	-
Breastfeeding	-	2 (29)	-	10 (71)

b)

Characteristic	Female infants (n=6)		Male infants (n=3)	
	Birth	Follow-up	Birth	Follow-up
Age at follow-up (days)	-	42 (25-63)	-	30 (29-31)
Weight (g)	1418 (888-4450)	2855 (900-6150)	3053 (2685-3420)	4073 (3930-4215)
Weight (centile)	39 (11-98)	20 (<1-85)	13 (3-23)	27 (19-35)
Weight gain velocity (g/week)	-	208 (3.4-242)	-	236 (192-281)
Length (cm)	39 (35-53)	51 (35-63)	51 (50-51)	54 (53-56)
Length (centile)	29 (11-66)	71 (<1-99)	18 (17-19)	43 (37-48)
Length gain velocity (cm/week)	-	1.1 (0-2.1)	-	0.9 (0.7-1.1)
Head circumference (cm)	29 (24-38)	34 (25-42)	34 (33-35)	39 (38-40)
Head circumference (centile)	48 (35-99)	55 (<1-100)	14 (4-24)	91 (87-94)
Head growth (cm/week)	-	0.5 (0.1-1.0)	-	1.1 (1.1-1.1)
NICU	5 (83)	-	1 (33)	-
Breastfeeding	-	0	-	0

c)

Characteristic	Female infants (n=6)		Male infants (n=10)	
	Birth	Follow-up	Birth	Follow-up
Age at follow-up (days)	-	43 (28-53)	-	43 (20-49)
Weight (g)	3040 (1940-3150)	4000 (2482-5350)	3255 (3110-3956)	4855 (4100-5900)
Weight (centile)	47 (19-56)	46 (4-93)	48 (18-94)	67 (32-99)
Weight gain velocity (g/week)	-	207 (136-293)	-	224 (180-623)
Length (cm)	50 (44-53)	56 (48-60)	51 (49-52)	56 (55-58)
Length (centile)	70 (35-89)	78 (27-100)	45 (28-77)	78 (29-100)
Length gain velocity (cm/week)	-	0.6 (0.4-1.5)	-	0.8 (0.6-2.5)
Head circumference (cm)	33 (31-35)	36 (33-40)	35 (33-36)	39 (36-40)
Head circumference (centile)	44 (10-85)	40 (23-99)	34 (6-99)	82 (26-100)
Head growth (cm/week)	-	0.6 (0.2-0.7)	-	0.7 (0.3-1.1)
NICU	0	-	1 (10)	-
Breastfeeding	-	3 (50)	-	5 (50)

Data are given as n (%) or median (full range)

[a], excluding one with unknown sex and mother lost to follow-up

NICU, neonatal intensive care unit; cTMA; complement mediated thrombotic microangiopathy